Randall C. Schatzman
Net Worth
Last updated:
What is Randall C. Schatzman net worth?
The estimated net worth of Dr. Randall C. Schatzman is at least $2,831,475 as of 9 Feb 2021. He owns shares worth $7,275 as insider and has received compensation worth at least $2,824,200 in Bolt Biotherapeutics, Inc..
What is the salary of Randall C. Schatzman?
Dr. Randall C. Schatzman salary is $706,050 per year as Chief Executive Officer & Director in Bolt Biotherapeutics, Inc..
How old is Randall C. Schatzman?
Dr. Randall C. Schatzman is 70 years old, born in 1955.
What stocks does Randall C. Schatzman currently own?
As insider, Dr. Randall C. Schatzman owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Bolt Biotherapeutics, Inc. (BOLT) | Chief Executive Officer & Director | 1,500 | $4.85 | $7,275 |
What does Bolt Biotherapeutics, Inc. do?
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Randall C. Schatzman insider trading
Bolt Biotherapeutics key executives
Bolt Biotherapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. David Dornan Ph.D. (47) Chief Scientific Officer
- Dr. Edith A. Perez M.D. (68) Chief Medical Officer
- Dr. Randall C. Schatzman (70) Chief Executive Officer & Director
- Mr. Grant Yonehiro (61) Chief Bus. Officer
- Mr. William P. Quinn (54) Chief Financial Officer